[Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban].

By M. Galli, C. Vassanelli. Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2001

861 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/8756bcb65be2a663142006ed645e8b78353fbc1b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. E. Amsterdam
2. E. Antman
3. E. Braunwald
4. Joseph S. Alpert
5. R. Brindis
6. Allan S. Jaffe
7. S. King
8. Patrick W. Serruys

Citations in the corpus

• ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients (2002, methodology): “In the interim, the TACTICS-TIMI 18 trial was reported (7).”
• Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. (2002, background): “l 1 have been shown to be associated with adverse cardiac outcomes in acute coronary syndromes([51,52]).”
• A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). (2002, result): “drome patients and up to 60% of non-primary percutaneous coronary interventions were performed as part of a routine policy, and not based on strict criteria stipulated in current guidelines([12,13]), in line with the favourable results attained with a routine invasive strategy in recent and contempo”
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, methodology): “For those not at high/intermediate risk, a delayed invasive approach is reasonable (173).”
• Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. (2002, background): “In these patients, a more aggressive interventional approach has been advocated.(22,23) This trend toward treatment earlier in the history of angina has, in part, fueled the dramatic growth (nearly 4-fold) in balloon angioplasty procedures performed in the United States from 1987 to 1999.”
• Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. (2001, methodology): “001) among those with elevated cTnI (Table 3) that was comparable to the 50% relative risk reduction in patients with elevated cTnT.(8) As such, the risk of recurrent events associated with elevated cardiac troponin was substantially attenuated by the early invasive strategy.”